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a  b  s  t  r  a  c  t
Background:  Measles  is a highly  infectious  illness  requiring  herd  immunity  of  95%  to  interrupt  transmis-
sion.  Measles  is  targeted  for elimination  in  China,  which  has  not  reached  elimination  goals  despite  high
vaccination  coverage.  We  developed  a population  proﬁle  of  measles  immunity  among  residents  aged
0–49 years  in  Tianjin,  China.
Methods:  Participants  were  either  from  community  population  registers  or community  immunization
records.  Measles  IgG  antibody  status  was  assessed  using  dried  blood  spots.  We  examined  the  association
between  measles  IgG antibody  status  and  independent  variables  including  urbanicity,  sex,  vaccination,
measles  history,  and  age.
Results:  2818  people  were  enrolled.  The  proportion  measles  IgG  negative  increased  from  50.7%  for  infants
aged  1 month  to 98.3%  for  those  aged  7 months.  After  8 months,  the  age  of  vaccination  eligibility,  the
proportion  of infants  and  children  measles  IgG  negative  decreased.  Overall,  7.8%  of  participants  9 months
of  age or  older  lacked  measles  immunity  including  over 10%  of  those  20–39  years.  Age and  vaccination
status  were  signiﬁcantly  associated  with  measles  IgG status  in  the  multivariable  model.  The  odds  of
positive  IgG  status  were  0.337  times  as  high  for unvaccinated  compared  to vaccinated  (95%  CI: 0.217,
0.524).
Conclusions:  The  proportion  of  persons  in  Tianjin,  China  immune  to measles  was  lower  than  herd  immu-
nity threshold  with  less  than 90%  of  people  aged  20–39  years  demonstrating  protection.  Immunization
programs  in Tianjin  have  been  successful  in  vaccinating  younger  age  groups  although  high  immuniza-
tion  coverage  in  infants  and children  alone  would not  provide  protective  herd  immunity,  given  the  large
proportion  of  non-immune  adults.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Measles has historically been a major cause of infectious
hildhood morbidity and mortality worldwide [1]. Over the last
wenty-ﬁve years, however, childhood deaths from measles glob-
lly have decreased dramatically, from 631,200 in 1990 to 145,700
n 2013, in part due to an increased international focus on global
radication [2,3]. Measles has now been successfully eliminated in
he Americas [4]. The other ﬁve WHO  regions have also set a target
∗ Corresponding author at: University of Michigan, Department of Epidemiol-
gy,  1415 Washington Heights, Ann Arbor, MI  48109, USA. Tel.: +1 734 936 1623;
ax:  +1 734 936 2084.
E-mail address: mboulton@umich.edu (M.L. Boulton).
ttp://dx.doi.org/10.1016/j.vaccine.2016.04.094
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access
y-nc-nd/4.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
for elimination by 2020 including China in the Pan Western Paciﬁc
Region [5,6]. Although China had originally established a national
goal of elimination by 2012, the target was  not met  and the coun-
try instead has recently experienced year-on-year increases in the
number of measles cases in 2013 and 2014 [7].
Measles is a highly communicable disease and at least 94% of the
population needs to be immune to interrupt endemic transmission
of disease [8]. Both active and passive immunity play important
roles in protecting against measles. Following infection with the
virus, an individual acquires both cellular and humoral immunity
with the latter detectable by the presence of measles IgG antibod-
ies in the serum which persist for decades [9]. Immunization with a
live measles-containing vaccine (MCV) elicits an immune response
similar to natural disease and both are forms of active immunity.
Passive immunity results from transplacental transfer of measles
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ntibody from mother to child generally during the third trimester
f pregnancy [10]. Whether mother’s immunity is derived from nat-
ral disease or immunization, the neonate’s passive immunity from
aternal antibodies theoretically protects against measles for sev-
ral months after birth. The duration of protection depends on the
uantity of antibody transferred and the rate of antibody decay
n the infant [11]. Antibodies present from passive immunity may
nterfere with an active immune response and it is recommended
hat vaccines be given after maternal antibodies have waned.
The recommended age for administration of the ﬁrst dose of
CV  falls between 8 to 12 months but varies by country. The tim-
ng of the initial dose represents a trade-off between providing the
accine early enough to prevent acquisition of disease, the age-
ependent risk of which differs across countries, balanced against
he potential for interference of the infant’s immune response by
aternal antibodies [12,13]. Moreover, young infants (i.e., aged ≤6
onths) develop less of a humoral response to measles vaccination
han older infants, no matter the mother’s immune status [14].
In China, routine measles vaccination has been available for chil-
ren as young as 8 months since 1966 [15]. However, the vaccine
as not widely administered until 1978 when it was  incorporated
nto the expanded program on immunization (EPI) and provided
or free to all children. A second dose of MCV  was added to China’s
PI in 1986 with a recommendation for administration at age 7
ears which was subsequently changed to age 18–24 months in
005 [16]. Some regions of China, including the Tianjin Municipal-
ty, provide an additional third dose at age 5 years. Since 2004, most
hinese provinces have conducted at least two supplementary
mmunization activities (SIAs), which have targeted all children
ge 8 months through 14 years, regardless of their previous vac-
ination status, in an effort to reduce transmission of measles
7,17].
China has had notable success in controlling measles since the
ntroduction of the vaccine. Although it has an annual birth cohort
f roughly 16 million children, the second largest in the world, vac-
ination coverage among children is generally high and at a level
hat exceeds herd immunity thresholds [18,19]. Measles vaccines
re provided free to both local residents and to internal migrants
ho relocate from rural to urban areas with SIAs reaching the
ajority of both local and migrant children [20]. Moreover, in
ost areas in China, governmental public health authority now has
ccess to comprehensive notiﬁable disease surveillance systems
nd immunization information systems to monitor measles cases,
etect outbreaks, and assess vaccine uptake [7]. Tianjin, located
pproximately 110 km southeast of Beijing in the northern part of
he country, is one of the most populous municipalities in China
nd serves as an important center of trade and economics. In 2014,
4.7 million people lived in Tianjin’s 16 districts, which span from
rban and suburban to rural areas. The dense population of urban
istricts reside in historical business areas, whereas suburban dis-
ricts and rural counties are more industrial and have less access
o public services [21,22]. Below the district/county level, residents
re registered to live in either a rural village or an urban community,
ith a total of 5073 villages/communities throughout the munic-
pality. In Tianjin, the municipal Centers for Disease Control and
revention (CDC) is responsible for serving the entire municipality
nd directs staff at district and local CDCs who carry out much of
he work in investigating outbreaks and evaluating immunization
rograms.
Given the challenges in the control of measles in China, assessing
opulation susceptibility is an important step in developing a better
nderstanding of the epidemiology of measles and in advanc-
ng an effective elimination strategy. Using information from a
opulation-based study of measles immunity in combination with
ase data from China’s public health surveillance system, we  devel-
ped a population proﬁle of measles immunity among residents34 (2016) 3037–3043
aged 0 through 49 years in Tianjin, and compared this proﬁle to
the distribution of measles cases across different age groups. We
anticipate that measles immunity will be low in both infants and
adults between 20 and 40 years since cases predominantly occur
in these two  age groups [23].
2. Methods
The targeted sample size consisted of 2800 individuals aged
0–49 years, with 200 individuals in each age category (groups
of 3 month blocks for infants <1 year of age, and 10-year age
blocks, thereafter). This sample size would allow us to gener-
ate age-stratiﬁed conﬁdence intervals of <14%, which is sufﬁcient
to compare measles immunity across age groups given immu-
nity levels reported in previous literature [24]. Women  aged
20–39 were oversampled in order to generate more precise con-
ﬁdence intervals and because we  concomitantly enrolled mothers
of every infant <1 year of age. The study enrolled participants
between November 2011 and April 2015 using a two-stage cluster
sample design. In the ﬁrst stage, 120 villages/communities were
selected through a probability proportionate to size procedure
while insuring that each district was represented by at least one vil-
lage/community. In the second stage, which was conducted within
each village/community, 12–32 people aged 1–49 years from the
village’s population registry were selected using an age-stratiﬁed
random selection procedure. The enrollment age cutoff date was
selected to be age 49 years old to correspond with introduction of
the measles vaccine in China in 1966 [25]. Because of a systematic
delay in listing infants in the village/community registry, infants
age <1 year were selected from records housed at local immu-
nization clinics. An age-stratiﬁed random sample of infants was
drawn from the clinic list although the number of infants from each
village/community varied because some small rural villages had
relatively few infants. The mother of each infant was also enrolled
in the study.
Prior to data collection, informed consent was obtained from
adult participants and the parents of minors enrolled in the study
were required to give their consent for the minor’s participation.
Study enrollees completed an in-person interview administered
by Tianjin CDC staff that required approximately 10 min  to com-
plete; parents or guardians were included in the interview for
any participant <18 years of age. The interview included ques-
tions about socio-demographic characteristics, vaccination history,
measles infection history, and exposure to congregate settings.
Five bloodspots from the participant’s ﬁnger were collected using
a single-use lancet, dropped onto ﬁlter paper, and dried. After
transport to the Tianjin CDC laboratory, dried bloodspots were
tested for measles IgG antibodies [26]. Measles IgG testing was
conducted using SERION ELISA classic measles IgG (quantitative)
Institut Virion/Serion GmbH, Würzberg, Germany. The laboratory
results were interpreted according to the guidelines from the Stan-
dardization Administration of the People’s Republic of China [27].
Threshold levels for IgG antibody test results were >200 IU/ml for
positive, 150–200 IU/ml for borderline, and <150 IU/ml for negative.
Each village/community was  classiﬁed as either urban, subur-
ban or rural based on which of the 16 districts it was located in;
the urban districts included Heping, Hedong, Hexi, Nankai, Hebei,
Hongqiao, and Binhai New Area; suburban districts were Jinnan,
Dongli, Xiqing, and Beichen; and rural districts comprised Baodi,
Wuqing, Ji, Jinghai, and Ninghe.
We compared the seroprevalence data to measles cases
recorded in the national notiﬁable disease registry, the China Infor-
mation System for Disease Control and Prevention (CISDCP). From
this source, we  tabulated the age of all 12,466 measles case-patients
reported from 2005 to 2014 in Tianjin.
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Table  1
Measles IgG antibody status among study participants ≥9 months of age, Tianjin, China, 2011–2015 (n = 2213).
Sample size Percent
Positive Negative Borderline
Overall 2213 87.8 10.0 2.3
Sex
Female 1616 87.4 10.2 2.4
Male  597 88.8 9.4 1.8
District type
Rural 707 89.5 8.5 2.0
Suburban 383 86.2 11.5 2.4
Urban 1123 87.2 10.4 2.4
Measles
vaccination status
No 276 83.0 14.9 2.2
Yes  794 92.7 5.2 2.1
Unknown 1142 85.5 12.2 2.4
History of measles
disease
No 1980 87.5 10.2 2.3
Yes  110 91.8 7.3 0.9
Unknown 123 88.6 8.9 2.4
Mother’s
education
Primary school 574 86.1 11.2 2.8
Middle school 702 87.3 10.5 2.1
High  school 332 88.9 8.7 2.4
Vocational 253 87.8 9.9 2.4
College/university or higher 178 93.3 4.5 2.3
None/unknown 174 87.4 12.1 0.6
Participant’s
Primary school 73 87.7 6.9 5.5
Middle school 492 85.4 12.8 1.8




































(≥18 years of age) Vocational 
College/university or higher 
None 
.1. Statistical analysis
To develop a population proﬁle of measles immunity, measles
gG status was compared by socio-demographic characteristics
sing basic descriptive statistics, including counts, frequencies and
roportions. For the multivariable logistic regression model, we
xamined the association between a dichotomous measles IgG
ntibody status (positive vs. borderline/negative) and several inde-
endent variables including urbanicity, sex, vaccination history,
easles history, and age. Urbanicity was determined to not be a
tatistically signiﬁcant predictor of measles IgG antibody status and
as therefore removed from the ﬁnal model. An ordinal logistic
egression model, with three outcomes (positive, borderline, and
egative measles IgG antibody status) and the same predictor vari-
bles, was also tested and yielded substantively similar results and
as thus discarded in favor of the simplest ﬁnal model. Odds ratios
OR), 95% conﬁdence intervals (CI), and p-values were reported
rom the ﬁnal model.
The data management for the study was  performed using
he OpenClinica database system version 3.3 (OpenClinica LLC,
altham, MA,  USA). Data analyses were conducted using SAS
oftware, version 9.3 (SAS Institute Inc., Cary, NC, USA). The
opulation-based measles immunity study was  approved by both
he University of Michigan Institutional Review Board (IRB) and the
ianjin Centers for Disease Control and Prevention Ethics Commit-
ee. The study received approval to not obtain assent from minors
s it is not customary in China for children to give assent when
arental permission has been granted. Public health surveillance
ata from CISDCP were collected for disease control purposes and
ere provided for use in this paper without individual identiﬁers
nd were, therefore, deemed exempt from regulatory review by the
niversity of Michigan IRB.
. ResultsA total of 2818 individuals comprising 1200 persons aged 1–49
ears, in addition to 809 mother-infant pairs (1618 individuals),
ere included. There were 173 people who declined to participate,86.3 11.4 2.4
84.9 12.6 2.6
88.0 12.0 0.0
and according to protocol, replacements from their communities
were found to maintain a sample size of 2818. Most partici-
pants (2050, 72.7%) participants tested positive for measles IgG, 72
(2.6%) tested as borderline and 696 (24.7%) were negative. Results
among the 2213 participants who were ≥9 months of age showed
1942 (87.8%) as measles IgG antibody positive; seropositivity was
comparable between males and females, and also by urbanicity,
mother’s education level, and participant education level for those
>18 years (Table 1). Participants who received at least one dose of
MCV  were more likely to be antibody positive (92.7%) compared to
those who had not received any doses of MCV  (83.0%). Similarly,
91.9% of participants who reported that they had been diagnosed
with measles were measles IgG antibody positive versus 87.5% of
those who  reported no prior measles.
Antibody status, vaccination status, and history of measles dis-
ease varied by age (Table 2). A signiﬁcant majority of children had
received at least one dose of MCV  among children 9–11 months
of age (97.6%) and 1–9 years of age (98.5%) while older children,
adolescents, and adults generally had much lower proportions of
vaccinated. Among participants age 10 years and older, the pro-
portion who  had an unknown vaccination status increased with
greater age. Among participants age 20–39, approximately 70%
were unsure whether they had received a dose of MCV. With
increasing age of participants, there also was  a comparable increase
in the proportion of individuals among each successive age group
who did not know their personal measles disease history, rang-
ing from <2% of those <20 years to 12.0% of adults aged 40–49
years.
The proportion of infants (i.e. <12 months of age) who tested
measles IgG antibody negative increased from 50.7% for those aged
1 month to 98.3% for participants aged 7 months (Fig. 1). After
vaccination age (i.e. 8 months), the proportion of infants and chil-
dren who were measles IgG antibody negative sharply decreased
(Figs. 1 and 2). Only 1.5% of children aged 1–9 years were IgG
negative. Among study participants over 10 years of age, a progres-
sively increasing proportion had no evidence of immunity against
measles, including 6% of those aged 10–14 years, 7% of those aged
15–19 years, 11% of those aged 20–29 years, and 16% of those aged
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Table  2
Measles sero-status, vaccination history, and disease history by age group, Tianjin, China, 2011–2015.
Sample size IgG status Vaccination status Disease history
% Positive % Yes % Unknown % Yes % Unknown
<9 months 605 17.9 8.9 0.0 0.0 0.0
9–12  months 204 94.6 97.6 0.0 0.0 0.4
1–9  years 200 97.5 98.5 1.0 1.0 0.5
10–19  years 213 89.2 73.2 25.4 1.9 1.9
20–29  years 827 86.2 16.0 69.8 5.3 5.6
30–39  years 560 81.3 14.5 69.1 6.3 8.2
40–49  years 209 93.8 13.9 58.9 12.0 12.0
Total  2818 72.7 30.1 40.6 3.9 4.4






(Fig. 2. Measles IgG antibody status and measles c
0–39 years (Fig. 2). The age distribution of measles cases in Tianjin
ollowed a U-shaped curve and was highest for those at 7 months
nd again at 20–39 years which correlated closely with the age
istribution of measles susceptibility based on IgG antibody status
Figs. 1 and 2).mong all participants, Tianjin, China, 2011–2015.
We  also examined measles immunity by birth cohort. For those
born before measles vaccination started in 1966, 97.6% (40/41)
were measles IgG positive. The percent positive by years of birth
were: 88.5% (291/329) of people born during 1966–1977 when
measles vaccine was  introduced in China; 83.6% (560/670) of
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Table  3
Demographic and other predictors of IgG seopositivity in Tianjin, China (n = 2818); a multivariable logistic regression model.
Odds ratio 95% Conﬁdence interval p value
Sex
Female 1.266 0.975 1.645 0.0769
Male Ref
Vaccinated
No 0.337 0.217 0.524 <.0001
Unknown 0.541 0.362 0.807 0.0026
Yes  Ref
Measles history
No 0.59 0.292 1.192 0.1415
Unknown 0.768 0.315 1.871 0.5615
Yes  Ref
Age
0  to <3 months 0.082 0.037 0.18 <.0001
3  to <6 months 0.018 0.007 0.042 <.0001
6  to <9 months 0.012 0.005 0.026 <.0001
9  to <12 months Ref
1  to 9 years 2.134 0.727 6.264 0.1678












































u20  to 29 years 0.54
30  to 39 years 0.38
40  to 49 years 1.46
eople born 1978–1985 when measles vaccine was  added to the
PI; 86.3% (669/775) of people born 1986–2004 when a second dose
f measles vaccine was added; and, 96.9% (154/159) of people over
8 months born since 2005, when the recommendation for admin-
stration of the second dose was adjusted from 7 years to age 18–24
onths.
The multivariable model (Table 3), shows a declining trend
f positive antibody status in older infants compared to younger
nfants, which once again increases after they reach the age of rec-
mmended vaccination (Table 3). Compared to infants age 9–11
onths, infants aged 0–2 months had 0.082 times the odds of hav-
ng immunity against measles (95% CI: 0.037, 0.180), and infants
–8 months had 0.012 times the odds of measles IgG antibody posi-
ivity (95% CI: 0.005, 0.026). When comparing participants between
he ages of 9–11 months with all other older age groups up to
ge 29 years, there was not a statistically signiﬁcant difference in
easles IgG antibody status. In contrast, adults 30–39 years, had
arkedly lower odds of being measles IgG antibody positive com-
ared to infants 9–11 months (OR: 0.385, 95% CI: 0.185, 0.801).
either sex nor reported history of measles disease was  signiﬁ-
antly associated with measles IgG antibody status, but vaccination
tatus was. Compared to participants who had at least one dose of
CV, those who received no MCV  had 0.337 times the odds of being
easles IgG antibody positive (95% CI: 0.217, 0.524). Participants
ith an unknown vaccination status also had lower odds of being
easles IgG antibody positive compared to participants known to
ave received at least one dose of MCV  (OR: 0.541, 95% CI: 0.362,
.807).
. Discussion
Measles is one of the most highly infectious diseases known
o humans [8], and has historically been a major contributor to
hildhood illness and death globally [1,2]. In this cross-sectional
eroprevalence study in Tianjin, China, there were progressively
ncreasing levels of age-related measles susceptibility in infants
xtending to 8 months, the age of vaccination eligibility, at which
oint most infants were immune. We  also found over 10% of
hose aged 20–39 years, an age range typically associated with
hild-bearing and rearing of infants and young children, had no
vidence of measles immunity. This bimodal age distribution for
eak measles susceptibility in infants and young adults places the
ormer at high risk for disease acquisition and potentially seri-
us illness. Additionally, the lack of measles immunity in infants
nder 8 months is difﬁcult to address since they are not eligible for0.263 1.129 0.1025
0.185 0.801 0.0107
0.596 3.592 0.4066
vaccination and China has not traditionally focused on immunizing
adults.
Theoretically, when more than 95% of a population is immune
to measles vis a vis a combination of active) and passive immunity,
the basic reproduction number will fall below 1, and endemic trans-
mission will be interrupted [8]. In this population-based study, we
found the proportion of people with measles immunity measles in
Tianjin was lower than the herd immunity threshold with less than
90% of people aged 10–39 years demonstrating sero-protection
against measles. A seroprevalence survey by He et al. in Zhejiang
province in 2009 also found that fewer than 90% of adults over 20
years of age were immune to measles, although over 95% of chil-
dren aged 2–9 years had immunity [28]. Lower levels of measles
immunity in adults have obvious relevance for the epidemiology
of disease and over half of all measles cases from 2005 to 2014 in
Tianjin were in individuals ≥20 years of age [23].
Low measles seropositivity in adults of reproductive age could
have major implications for infants since it could result in non-
immune parents caring for or otherwise having contact with
newborns and infants too young for vaccination. The high vacci-
nation coverage in older infants and young children, and resulting
high measles seropositivity, is helpful to control efforts but in terms
of transmission is likely mitigated by China’s one-child policy with
infants predominantly in contact with parents and grandparents
(who may  be susceptible), and not older, recently vaccinated chil-
dren Importantly, vaccination coverage levels should not be simply
equated with population immunity, which previous studies have
done [29]. This is particularly true for China, where many adults
may  not be immune from vaccination given that widespread adop-
tion of a 2-dose vaccination schedule only occurred within the past
3 decades.
We  found that with increasing age, neonates rapidly lost mea-
surable antibody protection. The level of transplacental maternal
antibodies in infants is a function of a number of key variables
including the quantity of antibody in the mother and the efﬁ-
ciency and duration of antibody placental transfer. The rate of
catabolic degradation over several months in the young infant is
itself related to nutrition and health status [10]. Early literature
on measles vaccine effectiveness showed that vaccine efﬁcacy was
lower at younger ages due to the presence of maternal antibod-
ies; a review of 70 studies showed vaccine efﬁcacy of 84.0% at
9–11 months of age and 92.5% at 12 months of age or older [30].
A more recent study found no statistical difference in the safety or
immunological results of measles–mumps–rubella vaccine admin-
istered at 8 months versus 12 months [31]. Because antibody load
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ith vaccination resulting in fewer antibodies produced relative to
atural infection, it may  be that in more recent years character-
zed by decreases in measles cases, fewer mothers having a history
f measles disease. Consequently, these vaccinated mothers who
ave never experienced measles disease, may  simply have fewer
ntibodies to transfer on to their fetus compared to previous gen-
rations exposed to endemic measles transmission [32,33].
Our ﬁnding that a low proportion of young adults have immuno-
ogical protection against measles has a signiﬁcant implication for
ontrol efforts in China. Targeting these individuals for vaccina-
ion, many of whom are in the peak years for childbearing, could
e a key component of a successful strategy to prevent disease
n their age group and subsequent transmission to young infants,
peciﬁcally, and to elimination efforts, generally. Tianjin requires
niversity students to provide evidence of measles vaccination
pon starting their educational program, but other institutions
nd programs frequented or used by young adults could also be
argeted for those young people who do not attend college. For
xample, parents and other family members could be offered the
ption of measles vaccination at prenatal or postnatal health check-
ps for their infants and children however mothers would not
e eligible for live measles vaccination at the prenatal appoint-
ent. However, it is important to note that similar programs to
ocoon children against pertussis in developed countries have not
een particularly successful because of difﬁculties in vaccinating
dults, especially fathers and other adult household contacts other
han mothers, during child health check-ups [34]. Another option
ight be to accelerate SIAs which could target a broad age range
f adults; during the measles elimination and post-elimination
hase in the Americas, 39 speed-up campaigns were conducted
o ensure that countries had adequate levels of measles immunity
mong adolescents and adults, and these interventions were gen-
rally considered important to the overall elimination effort [4].
ther venues for vaccinating young adults could also be considered,
xpanding the current program of immunizing college matricu-
ants to any older adolescent attending a trade school or training
or service industries or other non-traditional venues where young
dults could be accessed.
.1. Strengths and limitations
This study is subject to a number of limitations. Measles IgG
ntibody status was measured by ELISA, and it has been previously
emonstrated that several decades after measles infection or vacci-
ation, antibodies may  not be measurable even though immunity is
resent which may  lead us to overestimate the number of seroneg-
tive individuals in the older age group [35]. Vaccination status
nd history of measles disease are both subject to recall bias, par-
icularly for older adults. The direction of the bias is not necessarily
nidirectional for either vaccination or disease history since partic-
pants may  not forget an event that actually happened (vaccination
r disease), or they may  confuse with related events (e.g. rubella
nfection or vaccination against another disease). The study also
ad a number of unique strengths. We  used a rigorous population-
ased sampling scheme, which allowed us to enroll residents from
iverse villages and communities throughout Tianjin, and we  sam-
led a large age range in order to better quantify the proﬁle of
easles immunity. Comparing our results to cases from a robust
urveillance system was another notable strength.
. ConclusionsThe measles control program in Tianjin has generally been suc-
essful in attaining high vaccination coverage in its target age group
nd young, vaccine age-eligible children demonstrate high levels of
[34 (2016) 3037–3043
sero-protection against measles. As China continues its pursuit of
an elimination endgame, insuring high immunization coverage in
children alone will not be adequate to realizing sufﬁcient levels of
population herd immunity, particularly given that a large propor-
tion of adults remain susceptible to measles. China should consider
additional strategies to vaccinate adults aged >20 years including
speed-up immunization campaigns and implementing mandatory
vaccination for all young adults entering a variety of career train-
ing venues beyond just university entrance, could be key based on
the large proportion of measles cases in that continue to occur in
adults, the relatively low proportion of adults who have immune
protection from measles, and given the high probability of con-
tact with susceptible infants who are not age-eligible for measles
vaccination.
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